We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lipid Particles Test Accurately Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 07 Apr 2011
A blood test for low-density lipoprotein (LDL) particles is a more accurate predictor of cardiovascular disease (CVD) events than LDL cholesterol (LDL-C).

A high value proprietary blood test using nuclear magnetic resonance (NMR) technology has demonstrated that the amount of cholesterol per low-density lipoprotein particle (LDL-P) is variable and related in part to particle size, with smaller particles carrying less cholesterol.

Scientists at Wake Forest University School of Medicine, (Winston-Salem, NC, USA), analyzed blood samples obtained at study onset from 5,598 middle-aged men and women free of cardiovascular disease, who participated in a prospective observational study. Participants were followed for a mean of 5.5 years for incident CVD events, including heart attack, coronary heart disease death, angina, stroke, stroke death, or other atherosclerotic or CVD death.

Of 319 total CVD events recorded, 159 occurred in persons with LDL-C and LDL-P numbers that disagreed. The CVD risk of these individuals tracked with LDL-P number regardless of levels of LDL-C and only LDL-P numbers were associated with incidence of CVD. LDL particle levels were measured using the NMR LipoProfile test (LipoScience Inc., Raleigh, NC, USA). LDL-P information can help clinicians personalize and refine LDL treatment decisions, particularly to minimize residual risk in patients with low LDL-C levels. Clinicians historically have used the LDL-C level, the amount of cholesterol carried within LDL particles, to determine how much treatment, if any, a patient needs.

David C. Goff, Jr., MD, PhD, an investigator in the study, said, "In many patients, the standard cholesterol test may not be sufficient to adequately manage LDL levels. Patients who achieve recommended LDL-C goals may not have achieved correspondingly low LDL-P levels and as a consequence, may need further LDL lowering." It is recommended that additional studies should be conducted to estimate the potential value of this information for the prevention of cardiovascular disease in the general population. The study was published online on February 14, 2011, in the Journal of Clinical Lipidology.

Related Links:
Wake Forest University
LipoScience Inc.





Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.